Published in Diagn Microbiol Infect Dis on October 01, 1996
Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother (1999) 7.94
mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 4.38
Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother (1997) 3.27
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995. Antimicrob Agents Chemother (2001) 3.23
Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.19
Molecular detection of antimicrobial resistance. Clin Microbiol Rev (2001) 2.31
Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 2.21
Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother (1998) 1.67
In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother (2000) 1.64
Presence of mefA and mefE genes in Streptococcus agalactiae. Antimicrob Agents Chemother (1999) 1.64
Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol (1999) 1.59
Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob Agents Chemother (2001) 1.50
Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.47
Rapid scoring of genes in microbial pan-genome-wide association studies with Scoary. Genome Biol (2016) 1.38
Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother (2005) 1.35
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother (2003) 1.30
Identification of the conjugative mef gene in clinical Acinetobacter junii and Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother (2000) 1.29
Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. J Clin Microbiol (2000) 1.29
Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates. J Clin Microbiol (2004) 1.27
Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob Agents Chemother (2002) 1.25
In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. Eur J Clin Microbiol Infect Dis (1997) 1.17
Distribution of mef(A) in gram-positive bacteria from healthy Portuguese children. Antimicrob Agents Chemother (2002) 1.16
Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J Clin Microbiol (2003) 1.09
Nasal carriage of a single clone of community-acquired methicillin-resistant Staphylococcus aureus among kindergarten attendees in northern Taiwan. BMC Infect Dis (2007) 1.05
Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob Agents Chemother (2001) 1.02
Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates. J Clin Microbiol (2004) 1.01
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob Agents Chemother (2005) 0.99
Changes in the nasal colonization with methicillin-resistant Staphylococcus aureus in children: 2004-2009. PLoS One (2010) 0.91
Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother (2003) 0.86
Ribosomal Resistance: Emerging Problems and Potential Solutions. Curr Infect Dis Rep (1999) 0.85
In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci. Antimicrob Agents Chemother (2001) 0.80
Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. Antimicrob Agents Chemother (2016) 0.79
Differences in the DNA sequences in the upstream attenuator region of erm(A) in clinical isolates of Streptococcus pyogenes and their correlation with macrolide/lincosamide resistance. Antimicrob Agents Chemother (2005) 0.78
Characterization of ermA in macrolide-susceptible strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 0.77
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother (1996) 6.01
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother (1986) 4.51
Introduction of pAM beta 1 into Listeria monocytogenes by conjugation and homology between native L. monocytogenes plasmids. Infect Immun (1984) 3.98
Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae. Antimicrob Agents Chemother (1985) 2.81
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother (1997) 2.63
Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother (1997) 2.47
Cognitive processes mediating behavioral change. J Pers Soc Psychol (1977) 2.46
Antibody to hepatitis C virus in German blood donors. Lancet (1989) 2.21
Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis (1999) 2.16
Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter (1996) 2.10
Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. Microb Drug Resist (2004) 1.97
Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin. Eur J Clin Microbiol Infect Dis (1988) 1.97
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86
Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother (1994) 1.62
In vitro evaluation of tigemonam, a novel oral monobactam. Antimicrob Agents Chemother (1987) 1.59
Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol (2003) 1.53
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol (2012) 1.49
Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.47
Comparison of glycemic response and insulin requirements after mixed meals of equal carbohydrate content in healthy, type-1, and type-2 diabetic man. Klin Wochenschr (1989) 1.46
Identification of a novel viral protein in infectious bursal disease virus-infected cells. J Gen Virol (1995) 1.45
Interactive Volume Exploration of Petascale Microscopy Data Streams Using a Visualization-Driven Virtual Memory Approach. IEEE Trans Vis Comput Graph (2012) 1.45
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.43
In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother (2013) 1.41
Hepatitis C viremia in German blood donors: serum alanine aminotransferase is not a valid marker for screening. Transfusion (1994) 1.40
Abnormal pentagastrin response in a patient with pseudohypoparathyroidism. Exp Clin Endocrinol Diabetes (2002) 1.40
Biocompatibility of alginates for grafting: impact of alginate molecular weight. Artif Cells Blood Substit Immobil Biotechnol (2003) 1.40
Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother (2013) 1.39
[Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II]. Dtsch Med Wochenschr (2000) 1.38
[Therapy of diabetes in adults using Glibornurid. Results and clinical studies]. Dtsch Med Wochenschr (1973) 1.38
Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism. J Clin Microbiol (1997) 1.37
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant (2003) 1.31
Effect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase. Antimicrob Agents Chemother (1991) 1.30
Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. Microb Drug Resist (1999) 1.30
Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther (2012) 1.29
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer (2001) 1.29
Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother (1999) 1.26
Transport and storage of Helicobacter pylori from gastric mucosal biopsies and clinical isolates. Eur J Clin Microbiol Infect Dis (1995) 1.25
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst (2000) 1.21
Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int (2006) 1.21
Lysobactin, a novel antibacterial agent produced by Lysobacter sp. II. Biological properties. J Antibiot (Tokyo) (1988) 1.18
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol (1999) 1.17
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol (1999) 1.16
Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest (1986) 1.16
In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob Agents Chemother (1994) 1.15
The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus. Diabetologia (1999) 1.14
Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol (2002) 1.11
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol (1996) 1.10
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol (2002) 1.09
Multilayer capsules: a promising microencapsulation system for transplantation of pancreatic islets. Biomaterials (2001) 1.09
Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis (1996) 1.09
The influence of PEEP ventilation on organ blood flow and peripheral oxygen delivery. Intensive Care Med (1982) 1.09
Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. Antimicrob Agents Chemother (1987) 1.08
Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest (1998) 1.08
Improved sensitivity in assays for binding of novel beta-lactam antibiotics to penicillin-binding proteins of Escherichia coli. Antimicrob Agents Chemother (1987) 1.08
Prolonged application of pressure in transluminal coronary angioplasty. Cathet Cardiovasc Diagn (1984) 1.08
Intranasal GnRH therapy of maldescended testes. Horm Metab Res (1975) 1.07
A second form of infectious bursal disease virus-associated tubule contains VP4. J Virol (1997) 1.07
Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res (1997) 1.06
Serum leptin is associated with serum uric acid concentrations in humans. Metabolism (1999) 1.05
In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother (1995) 1.05
Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost (2005) 1.05
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol (2001) 1.04
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol (2003) 1.03
Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob Agents Chemother (2001) 1.02
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol (2001) 1.02
[Polyglandular autoimmune syndrome type II: epidemiology and forms of manifestation]. Dtsch Med Wochenschr (1999) 1.01
Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. J Med Chem (2000) 1.01
American Academy of Pediatrics Report of the Subcommittee on Assessment and Methodologic Issues in the Management of Pain in Childhood Cancer. Pediatrics (1990) 0.98
Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob Agents Chemother (2001) 0.97
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. J Thromb Haemost (2007) 0.97
Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) (2000) 0.96
Reversed portal vein pulsatility on Doppler ultrasound secondary to an iatrogenic mediastinal haematoma. Br J Radiol (2001) 0.96
Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet (1984) 0.96
High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer (1998) 0.95
Blepharmone: a conjugation-inducing glycoprotein in the ciliate blepharisma. Science (1974) 0.95
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer (2000) 0.94
Eligibility for home treatment of deep vein thrombosis: prospective study. BMJ (2001) 0.94
HLA antigens and immunoresponsiveness to insulin in insulin-dependent diabetes mellitus. Tissue Antigens (1976) 0.92
Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med (1995) 0.92
Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin. Blood Coagul Fibrinolysis (2001) 0.91
Kill kinetics of antimicrobial agents against Helicobacter pylori. J Antimicrob Chemother (1996) 0.90
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol (1998) 0.90